ELOX Stock Forecast: Eloxx Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$11

The median 12-month analyst price target for Eloxx Pharmaceuticals, Inc. is $39. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$43.7M
Ticker Nerd rank
18/ 100
Median analyst target
$39
Analysts covering
5
Revenue$0.0
Operating income−$4.5M
Net income−$4.5M
Free cash flow−$4.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Eloxx Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
18/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
82
Revisions
57
Volatility
53
Value
18
Issuance
18
Growth
10
Quality
5
Accruals
5

Momentum (82): The shares have been drifting up relative to others.

Accruals (5): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ELOX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELOX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says5 analysts
5
Buy
0
Hold
0
Sell
$32
Low
$39
Median
$40
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 7 moved it down.

DateFirmActionRatingTarget
28 Oct 2026GuggenheimMaintainsBuy$43 → $40
15 Oct 2026Cantor FitzgeraldInitiatesOverweight—
18 Sept 2026Leerink PartnersInitiatesOutperform$32
24 Aug 2026GuggenheimReiteratesBuy$43
20 Aug 2026LUCID CAPITAL MARKETSInitiatesBuy$38
22 July 2026LifeSci CapitalInitiatesOutperform$40
20 July 2026GuggenheimInitiatesBuy$43
11 July 2023OppenheimerMaintainsOutperform$50 → $55
6 Apr 2023OppenheimerReiteratesOutperform—
23 May 2022Piper SandlerMaintainsOverweight$4.00 → $1.50
9 May 2022HC Wainwright & Co.MaintainsNeutral$1.00 → $0.50
17 Dec 2021OppenheimerInitiatesOutperform—
18 Nov 2021HC Wainwright & Co.MaintainsNeutral$2.00 → $1.00
11 Nov 2021HC Wainwright & Co.MaintainsNeutral$3.00 → $2.00
30 June 2021MizuhoInitiatesBuy—
27 May 2021B. Riley SecuritiesInitiatesBuy—
11 June 2020CitigroupDowngradeNeutral$11 → $4.00
8 May 2020Janney CapitalMaintainsBuy—
8 May 2020Janney Montgomery ScottMaintainsBuy$13 → $10
6 Mar 2020H.C. WainwrightReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ELOX.

Market Radar

This page is one stock. Monday covers all of them.

ELOX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

ELOX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
5.6×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
1.1×

Cheaper than 68% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−113.8%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eloxx Pharmaceuticals, Inc. has a market value of $43.7M.

  • Shares outstanding: 3.4M.

  • Trailing P/E: 5.6×.

  • Eloxx Pharmaceuticals, Inc. employs 10 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ELOX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELOXEloxx Pharmaceuticals, Inc.$43.7M18
SPROSpero Therapeutics, Inc.$43.2M32
CRBPCorbus Pharmaceuticals Holdings, Inc.$42.4M12
ANVSAnnovis Bio, Inc.$44.1M16
OSTXOS Therapies, Inc.$42.0M23
GANXGain Therapeutics, Inc.$44.5M32
BMEABiomea Fusion, Inc.$41.7M46

Take a look at ELOX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Eloxx Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ELOX

What is the ELOX stock price forecast for 2026-2027?

The median 12-month analyst price target for Eloxx Pharmaceuticals, Inc. is $39, with estimates ranging from $32 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELOX stock a buy right now?

Of the 5 analysts covering Eloxx Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eloxx Pharmaceuticals, Inc. 18 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELOX?

As at 21 Nov 2026, Eloxx Pharmaceuticals, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (82 of 100).

Will ELOX stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts is $39, and Ticker Nerd's factor model ranks Eloxx Pharmaceuticals, Inc. 18 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELOX stock forecast for 2030?

No analyst covering Eloxx Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELOX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $40 over the next 12 months.

What does Eloxx Pharmaceuticals, Inc. do?

Eloxx Pharmaceuticals, Inc. Common Stock represents equity in Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel small-molecule medicines that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. The company’s current pipeline centers on exaluren, which is being studied for rare kidney diseases such as nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease, along with related ultra-rare genetic conditions.

Company

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc. Common Stock represents equity in Eloxx Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel small-molecule medicines that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations. The company’s current pipeline centers on exaluren, which is being studied for rare kidney diseases such as nonsense mutation Alport syndrome and autosomal dominant polycystic kidney disease, along with related ultra-rare genetic conditions. Eloxx also has a licensed program, ZKN-013, being advanced for rare dermatological diseases associated with nonsense mutations. Headquartered in Arlington, Massachusetts, Eloxx Pharmaceuticals operates in the biotechnology sector and serves a specialized niche in precision therapies for rare and ultra-rare disorders.

CEO Mr. Sumit Aggarwal M.B.A. · 10 employees · United States · https://www.eloxxpharma.com